相关实验视频

Updated: Jul 9, 2025

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

奥帕加尼布 (ABC294640) 诱导免疫性瘤细胞死亡并增强检查点抗体疗法

Lynn W Maines¹, Staci N Keller¹, Charles D Smith¹

¹Apogee Biotechnology Corporation, 1214 Research Blvd, Suite 2015, Hummelstown, PA 17036, USA.

International journal of molecular sciences

|December 9, 2023

概括

奥帕加尼布诱导瘤细胞的免疫细胞死亡 (ICD),增强检查点抑制剂免疫疗法的有效性,如抗PD-1和抗CTLA-4抗体,以改善癌症治疗结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

检查点抑制剂 (CTLA-4,PD-1,PD-L1) 改善了某些癌症的结果,但在许多患者中缺乏有效性.
瘤细胞中的免疫细胞死亡 (ICD) 可以增强抗癌免疫反应并提高免疫疗法的疗效.
脂代谢,特别是涉及脂酶,调节癌细胞死亡,增殖和免疫反应.

研究的目的:

为了调查opaganib,一个基酶-2抑制剂,可以诱导瘤细胞中的ICD.
评估阿帕加尼布诱导的ICD是否增强检查点抑制剂抗体 (抗PD-1,抗CTLA-4,抗PD-L1) 的抗瘤活性.

主要方法:

在体外评估opaganib对各种瘤细胞系中的ICD标志物 (calreticulin) 表达的影响.
在体内免疫试验中,使用Opaganib治疗的瘤细胞 (B16黑色素瘤,LLC,Neuro-2a) 在同源性小鼠中进行免疫试验.
在小鼠瘤模型中对opaganib与抗PD-1,抗CTLA-4和抗PD-L1抗体的联合研究.

主要成果:

在实验室中,opaganib治疗增加了瘤细胞的表面calreticulin表达.
用奥帕加尼布治疗的细胞免疫在小鼠中抑制了随后的瘤生长,表明诱导的ICD和交叉免疫力.
与抗PD-1,抗CTLA-4或抗PD-L1抗体相结合的奥帕加尼布联合治疗显著增强了瘤抑制和改善了与单一治疗相比的小鼠存活率.

结论:

奥帕加尼布有效诱导瘤细胞中的免疫细胞死亡.
奥帕加尼布增强了检查点抑制剂抗体的治疗疗效,为改善癌症免疫治疗提供了一个有前途的策略.

关键词:

美国ABC29464040号检查点的抗体检查点的抗体.免疫性细胞死亡免疫性细胞死亡免疫疗法免疫疗法这就是Opaganib的意义.球脂质是指脂质中的一种.

更多相关视频

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...